Search the Newsreel

Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Pyxis Oncology, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net loss of $25.35 million, an increase from $18.35 million in the prior year, with a basic and …

Pyxis Oncology Q2 loss widens 38%, misses EPS estimate

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million, or ($0.40) per share, which widened by 38% year-over-year and missed analyst estimates due to a significant increase in general and administrative expenses. The company secured $50 million in new financing, extending its …

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary

Pyxis Oncology, Inc. reported its Q2 2026 financial results, showing $0 in revenue and a net loss of $25.35M, leading to a diluted EPS of $(0.40). This compares to Q2 2025 revenue of $2.82M and a net loss of $18.35M. The company highlighted continued …

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com

This article announces that Pyxis Oncology Inc. has filed a Form 8K on August 13. The brief piece provides no further details beyond the filing announcement. It includes stock market data and other Investing.com features.

Pyxis Oncology expects two MICVO cancer-study data updates in 2026

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million but strengthened its financial position with a private placement of up to $114 million, extending its cash runway into Q2 2027. The company anticipates key clinical data readouts for its lead candidate, MICVO, …

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology (Nasdaq: PYXS) reported its second-quarter 2026 financial results, highlighting progress in its MICVO clinical development programs and an extended cash runway into Q2 2027 following a $114 million private placement. The company is set to release updated data from the MICVO Phase …

Pyxis Oncology Inc expected to post a loss of 35 cents a share - Earnings Preview

Pyxis Oncology Inc is projected to report a loss of 35 cents per share, according to an earnings preview. This information suggests an upcoming financial disclosure for the company. The full article is available to subscribers of TradingView.

Pyxis Oncology Inc (PYXS) Stock News Today

This article from TradingKey provides current stock news for Pyxis Oncology Inc (PYXS). It lists the company's stock price, market capitalization, and indicates that more news, earnings, and analyst ratings will be updated soon. The content serves as a placeholder for ongoing updates regarding …

Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.34 per share and revenue of $33,000, continuing a trend of projected annual losses of around $1 per share. Despite mixed …

Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pyxis Oncology Inc (PYXS), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 10 analysts have given the stock a "Buy" trend, with an average price target of $7.70. The article …

Enterprise value to EBIT forward of Pyxis Oncology, Inc. – NASDAQ:PYXS

This article provides financial information for Pyxis Oncology, Inc. (NASDAQ: PYXS), specifically focusing on its enterprise value to EBIT forward ratio. It highlights that the data is presented by TradingView, a platform offering various market tools and financial insights. The content is primarily a …

Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company

Wells Fargo & Company has upgraded Pyxis Oncology (NASDAQ:PYXS) to a "strong-buy" rating. Despite the upgrade, the company reported a quarterly EPS of -$0.37, missing analyst estimates. Institutional investors and hedge funds currently hold 39.07% of the company's stock, which has an average analyst …

Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com

Wells Fargo has initiated coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with an overweight rating and a price target of $12.00, citing the potential of its MICVO treatment for head and neck squamous cell carcinoma. Despite a recent nine percent decline, the stock has seen …

Wells Fargo Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12

Wells Fargo has initiated coverage on Pyxis Oncology (PYXS.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This initiation suggests a positive outlook from Wells Fargo regarding Pyxis Oncology's future performance.

Pyxis Oncology Inc (PYXS) Balance Sheet

This article provides a detailed balance sheet for Pyxis Oncology Inc (PYXS), presenting both quarterly and annual financial data. It allows users to assess the company's financial health, examine fundamentals, and calculate key financial ratios related to liquidity, leverage, and return on equity. The …

Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pyxis Oncology Inc. (PYXS), outlining its major shareholders, investor types, and institutional holdings. It provides a breakdown of proportions held by entities like Pfizer Inc., Laurion Capital Management LP, and various categories such as hedge funds and …

Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pyxis Oncology Inc's (PYXS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and offers no dividend data. The article also presents current stock performance data and …

Pyxis Oncology Inc (PYXS) Institutional Confidence

Pyxis Oncology Inc (PYXS) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 2.86% quarter-over-quarter to 40.97%. Key institutional shareholders include Pfizer Inc, Laurion Capital Management LP, …

Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis

Pyxis Oncology Inc (PYXS) has a current valuation score of 6.51, placing it 325 out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -2.01, significantly below its recent high but above its recent low. Other valuation metrics like …

PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070

Pyxis Oncology Inc (PYXS) is a clinical-stage biotechnology company focused on developing therapeutics for difficult-to-treat cancers. The company's stock shows strong fundamentals and high growth potential, despite recent weak market performance, with a current "Buy" rating from analysts and a target price of $6.75. …

PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress

Pyxis Oncology (PYXS) stock is trading steady as the company emphasizes its strong cash position and disciplined spending, projecting a multi-year funding runway into at least 2026. The firm reported a reduced net loss and lower operating cash burn in its latest quarterly update …

Pyxis Oncology (PYXS) Q1 2026 Earnings: EPS Beat on Lower Operating Expenses, Stock Surges 13% - Profit Announcement

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received an average rating of "Moderate Buy" from analysts, with a consensus 12-month price target of $6.86. Despite this positive outlook, recent analyst actions have been mixed, and the company reported a quarterly loss of ($0.37) EPS, missing estimates. …

Pyxis Oncology Q1 2026 Earnings: Narrower Loss Per Share Drives Positive Stock Movement - Earnings Quality Analysis

Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Stock - Short-Term Outlook

Pyxis Oncology (PYXS) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Stock Surge - Interim Report

PYXS Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Rises 2.76% - Return On Equity

Pyxis Oncology, Inc. Actuals & Estimates (NASDAQ:PYXS)

PYXS Forecast — Price Target — Prediction for 2027

Pyxis Oncology (PYXS) Gains 3.2% as Shares Approach Key Resistance - Narrow Range Breakout

Pyxis Oncology (PYXS) Q1 2026 Earnings: Small EPS Beat Drives 6.8% Stock Gain Amid No Revenue

Pyxis Oncology Edges Higher as Shares Test Key Resistance Levels - MAMA Signal

Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives